**Short Communication**

The manuscript should be written in English in a clear, direct and active style. All pages must be numbered sequentially and mark the line number, facilitating in the reviewing and editing of the manuscript. For Chinese authors, please also submit Chinese abstract after the manuscript be accepted via email (ccmp2020@163.com) for academic promotion. The length of the paper should be 1500-2500 words, with maximum count of 3 figure and table combined.

***Title page***

Title page should include title, all the author(s) full name (first name and last name) and complete affiliation/address, corresponding author(s) names, complete affiliation/address, along with email addresses of all listed authors.

**Title**

The title of the article should be precise and brief and must not exceed 15 characters. Author should avoid to use non-standard abbreviations and question marks in titles.

**Abstract**

Please minimize the use of abbreviations and do not cite references in the abstract. The abstract should briefly summarize the aim, findings or purpose of the article. The Abstract should not exceed 300 words.

**Keywords**

Totally 3 to 5 keywords must be provided. Choose important and relevant keywords that researchers in your field will be searching for so that your paper will appear in a database search.

***Main text***

**1.Introduction**

The Background section should explain the background to the study, its aims, a summary of the existing literature and why this study was necessary.

**2. Materials and Methods** (for pharmacological research) or **Methods** (for clinical research)

The Methods section should include: the design and setting of the study, the description of materials and methods used, and the type of statistical analysis used, including a power calculation if appropriate.

1. **Results and discussion**

This should include the findings of the study including, if appropriate, results of statistical analysis which must be included either in the text or as tables and figures. This section should discuss the implications of the findings in context of existing research and highlight limitations of the study.

1. **Conclusions**

This should state clearly the main conclusions and provide an explanation of the importance and relevance of the study to the field.

**Ethical Approval**

If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them (or “Not applicable.”).

**Data Availability**

Declare the link or method to access the original data supporting the findings of the study.

E.g. The data that support the findings of this study are openly available in [repository name] at [URL].

**Funding (optional)**

The authors need to declare the funding sources of their manuscripts clearly by providing the name of the funding agency or financial support along with allotted grant/award number in round brackets (if applied).

E.g. This study was supported by the National Natural Science Foundation of China ([82000047](https://www.sciencedirect.com/science/article/pii/S0378874123009303%22%20%5Cl%20%22gs1) and [82000034](https://www.sciencedirect.com/science/article/pii/S0378874123009303%22%20%5Cl%20%22gs1)), China Postdoctoral Science Foundation ([2023M000083](https://www.sciencedirect.com/science/article/pii/S0378874123009303%22%20%5Cl%20%22gs2)), and Basic and Applied Basic Research Foundation of Guangdong Province ([2020A15151100](https://www.sciencedirect.com/science/article/pii/S0378874123009303%22%20%5Cl%20%22gs4)00).

**ORCID**

E.g. XXXX Yang, https://orcid.org/0000-0002-9300-XXXX (ORCID of the corresponding author).

**Declaration of Competing Interest**

E.g. The authors declare that they have no known competing interests or personal relationships that could have appeared to influence the work reported in this paper.

**Credit authorship contribution statement**

E.g. XXX Gao: Formal analysis, Writing-original draft, Writing-review & editing, Funding acquisition. XXX Shi: Methodology, Validation, Formal analysis. XXX Xie: Validation, Investigation.

**Acknowledgement (optional)**

E.g. We appreciate the great experimental support from the Public Platform of Pharmaceutical Research Center, Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University.

**Supplementary Materials (optional)**

E.g. <https://ars.els-cdn.com/content/image/1-s2.0-S2772371223000293-mmc1.xlsx>.

**References**

References should be limited to no more than 20.

***More details can be found at https://ccmp.zcmu.edu.cn/zjzyy/news/view/20210617113450001.***